Foziah Jabbar Alshamrani

Foziah Jabbar Alshamrani

Auto-generated profile, based on publicly available information

Foziah Jabbar Alshamrani


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2020 in Molecules
Verified
Journal Article
Open access
PDF file
BABushra Adalat
Bushra Adalat
DRDr. Fazal Rahim
Dr. Fazal Rahim
MTMuhammad Taha
Muhammad Taha
FAFoziah J. Alshamrani
Foziah J. Alshamrani
EAEl Hassane Anouar
El Hassane Anouar
ZZZainul Amiruddin Zakaria
Zainul Amiruddin Zakaria
We synthesized 10 analogs of benzimidazole-based thiosemicarbazide 1 (a–j) and 13 benzimidazole-based Schiff bases 2 (a–m), and characterized by various spectroscopic techniques and evaluated in vitro for acetylcholinesterase (AchE) and butyrylcholinesterase (BchE) inhibition activities. All the synthesized analogs showed varying degrees of acetylcholinesterase and butyrylcholinesterase inhibitory potentials in comparison to the standard drug (IC50 = 0.016 and 4.5 µM. Amongst these analogs 1 (a–j), compounds 1b, 1c, and 1g having IC50 values 1.30, 0.60, and 2.40 µM, respectively, showed good acetylcholinesterase inhibition when compared with the standard. These compounds also showed moderate butyrylcholinesterase inhibition having IC50 values of 2.40, 1.50, and 2.40 µM, respectively. The rest of the compounds of this series also showed moderate to weak inhibition. While amongst the second series of analogs 2 (a–m), compounds 2c, 2e, and 2h having IC50 values of 1.50, 0.60, and 0.90 µM, respectively, showed moderate acetylcholinesterase inhibition when compared to donepezil. Structure Aactivity Relation of both synthesized series has been carried out. The binding interactions between the synthesized analogs and the enzymes were identified through molecular docking simulations.

23 October 2019 in Molecules
Verified
Journal Article
Open access
PDF file
MTMuhammad Taha
Muhammad Taha
FAFoziah J. Alshamrani
Foziah J. Alshamrani
DRDr. Fazal Rahim
Dr. Fazal Rahim
SHShawkat Hayat
Shawkat Hayat
HUHayat Ullah
Hayat Ullah
FNFarzana Naz
Farzana Naz
A new class of triazinoindole-bearing thiosemicarbazides (1–25) was synthesized and evaluated for α-glucosidase inhibitory potential. All synthesized analogs exhibited excellent inhibitory potential, with IC50 values ranging from 1.30 ± 0.01 to 35.80 ± 0.80 μM when compared to standard acarbose (an IC50 value of 38.60 ± 0.20 μM). Among the series, analogs 1 and 23 were found to be the most potent, with IC50 values of 1.30 ± 0.05 and 1.30 ± 0.01 μM, respectively. The structure–activity relationship (SAR) was mainly based upon bringing about different substituents on the phenyl rings. To confirm the binding interactions, a molecular docking study was performed.

1 January 2018 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
SNsaima Nazish
saima Nazish
RSRizwana Shahid
Rizwana Shahid
AZAzra Zafar
Azra Zafar
FAFoziah Alshamrani
Foziah Alshamrani
ASAbdullah Al Sulaiman
Abdullah Al Sulaiman
FAFahd A Alkhamis
Fahd A Alkhamis
Nazish S, et al. J Clin Neurol. 2018 Jul;14(3):359-365. https://doi.org/10.3988/jcn.2018.14.3.359

1 June 2021 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Open access
MJMohammed Al Jumah
Mohammed Al Jumah
AAAhmad Abdulaziz Abulaban
Ahmad Abdulaziz Abulaban
HAHani Aggad
Hani Aggad
RBReem Al Bunyan
Reem Al Bunyan
MAMona Alkhawajah
Mona Alkhawajah
SSSahar Shami
Sahar Shami
Disease-modifying therapies (DMT) for relapsing-remitting MS (RRMS) act on the immune system, suggesting a need for caution during the SARS-CoV2/Covid-19 pandemic. A group of experts in MS care from Saudi Arabia convened to consider the impact of Covid-19 on MS care in that country, and to develop consensus recommendations on the current application of DMT therapy. Covid-19 has led to disruption to the care of MS in Saudi Arabia as elsewhere. The Expert Panel considered a DMT's overall tolerability/safety profile to be the most important consideration on whether or not to prescribe at this time. Treatment can be started or continued with interferon beta, teriflunomide, dimethyl fumarate, or natalizumab, as these DMTs are not associated with increased risk of infection (there was no consensus on the initiation of other DMTs). A consensus also supported continuing treatment regimens with fingolimod (or siponimod) and cladribine tablets for a patient without active Covid-19. No DMT should be imitated in a patient with active Covid-19, and (only) interferon beta could be continued in the case of Covid-19 infection. Vaccination against Covid-19 is a therapeutic priority for people with MS. New treatment should be delayed for 2–4 weeks for vaccination. Where treatment is already ongoing, vaccination against Covid-19 should be administered immediately without disruption of treatment (first-line DMTs, natalizumab, fingolimod), when lymphocytes have recovered sufficiently (cladribine tablets, alemtuzumab) or 4 months after the last dose (ocrelizumab). These recommendations will need to be refined and updated as new clinical evidence in this area emerges.


21 November 2016 in Expert Review of Neurotherapeutics
Verified
Journal Article
Closed access
FAFoziah Alshamrani
Foziah Alshamrani
HAhind Alnajashi
hind Alnajashi
MFM Freedman
M Freedman
Introduction: Neurologists are frequently consulted for patients who have white matter lesions discovered incidentally on their brain MRI, performed for reasons other than suspecting a demyelinating disease. The referring physician will question if the person has multiple sclerosis (MS). If the MRI is typical for MS but there are no clinical symptoms or signs suggestive of a demyelinating disorder, patients are diagnosed as having a Radiologically Isolated Syndrome (RIS). Areas covered: This is a timely review on RIS with a focus on treatment considerations. Expert commentary: Multiple studies have tried to identify common predictive factors for conversion of RIS to clinical MS, the strongest thus far being an asymptomatic cervical spinal cord lesion. Treatment of RIS is highly controversial, but early treatment in carefully selected patients might improve long term outcome.